EDIT vs NSC · rev $32.3M vs P/E 18, rev $12.12B
Editas Medicine Inc (EDIT) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported NSC revenue for 2024-12-31 was $12.12B. Net income was $2.62B. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
EDIT currently screens at market cap $375.2M. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the EDIT and NSC stock pages for the full models.
Not investment advice.